| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C49-248
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C253-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C49-255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C45-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C45-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C49-248
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C253-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C45-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C45-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C45-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C49-255 |
| filingDate |
2003-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2006-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2006508149-A |
| titleOfInvention |
Novel process for the preparation of 1,5-bis (4-hydroxy-3-methoxyphenyl) -penta-1,4-dien-3-one and derivatives having antitumor properties |
| abstract |
The present invention relates to a process for the production of 1,5-bis (4-hydroxy-3-methoxyphenyl) -penta-1,4-dien-3-one and derivatives having antitumor properties: 9 different types of human cancer A sample called 37 compounds showing cell growth inhibitory activity (growth inhibition) at the evaluated concentration and killer cell activity (cell death) from a concentration of 0.25 μg / ml against the cell line was obtained by ultrasonic techniques. Rate and high purity. This compound has an LD50 equal to 8.54 g / Kg. This means that the product can itself be considered substantially non-toxic. The anticancer drug doxorubicin, used as a control in all of these studies, is a highly toxic product (LD50 of 20 mg / Kg) and is a Mama NCI-ADR cell line (a cell that exhibits a phenotype of resistance to many drugs). ) And therefore our product showed strong cytostatic activity. Other derivatives also showed strong cytostatic activity, especially those referred to as EHB1 compounds. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010501473-A |
| priorityDate |
2002-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |